Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncopeptides AB ( (SE:ONCO) ) has issued an update.
Oncopeptides AB, a Stockholm-listed biotech company focused on targeted therapies for difficult-to-treat cancers, develops and commercializes oncology drugs based on its proprietary Peptide Drug Conjugate and SPiKE platforms. Its flagship cancer therapy is being rolled out across Europe, supported by partnership agreements in South Korea, the Middle East, Africa and other territories, underlining its ambition to broaden its global market reach.
The company announced it will publish its fourth-quarter and full-year 2025 results on February 19, 2026, and has invited investors, analysts and media to an English-language webcast and teleconference presentation hosted by its CEO and CFO. The planned Q&A session signals ongoing engagement with capital markets, and the disclosure of year-end figures is expected to give stakeholders clearer insight into Oncopeptides’ commercial traction, geographic expansion and progress across its oncology pipeline.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK3.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotechnology company specializing in targeted therapies for difficult-to-treat cancers. Using its proprietary Peptide Drug Conjugate and SPiKE technology platforms, it develops compounds that selectively deliver cytotoxic agents into cancer cells, and it is commercializing its flagship cancer drug in Europe while expanding via partnerships in South Korea, the Middle East, Africa and other markets.
Founded in 2000, the company employs around 80 people and operates in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm under the ticker ONCO, positioning it as a niche oncology player in the European biotech landscape with a focus on innovative cancer treatments and strategic international collaborations.
Average Trading Volume: 1,891,555
Technical Sentiment Signal: Sell
Current Market Cap: SEK709.8M
For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.